Comparative Pharmacology
Head-to-head clinical analysis: NITROLINGUAL versus NITROMIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROLINGUAL versus NITROMIST.
NITROLINGUAL vs NITROMIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylyl cyclase, increasing cGMP levels in vascular smooth muscle. This leads to dephosphorylation of myosin light chains, causing vasodilation. It predominantly dilates venous capacitance vessels, reducing preload, and to a lesser extent dilates arterioles, reducing afterload.
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing cGMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
1 to 2 sprays (0.4 mg/spray) sublingually at onset of angina, may repeat every 5 minutes up to 3 doses; prophylactic use: 1 spray 5-10 minutes before activity.
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
None Documented
None Documented
2-3 minutes for sublingual nitroglycerin; rapid decline due to extensive first-pass metabolism and high clearance (30-40 L/min). Clinical context: extremely short half-life necessitates continuous or frequent dosing for sustained effect.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Renal (primarily as glucuronide conjugates and denitrated metabolites): ~60-80%; Fecal: ~20-40%; Biliary: negligible. Less than 1% excreted unchanged.
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator